Singapore markets closed
  • Straits Times Index

    3,359.65
    -18.00 (-0.53%)
     
  • S&P 500

    4,119.21
    +42.61 (+1.05%)
     
  • Dow

    34,092.96
    +6.92 (+0.02%)
     
  • Nasdaq

    11,816.32
    +231.77 (+2.00%)
     
  • BTC-USD

    23,816.92
    +826.44 (+3.59%)
     
  • CMC Crypto 200

    543.28
    +300.60 (+123.87%)
     
  • FTSE 100

    7,808.46
    +47.35 (+0.61%)
     
  • Gold

    1,971.80
    +29.00 (+1.49%)
     
  • Crude Oil

    76.67
    +0.26 (+0.34%)
     
  • 10-Yr Bond

    3.3970
    0.0000 (0.00%)
     
  • Nikkei

    27,402.05
    +55.17 (+0.20%)
     
  • Hang Seng

    21,958.36
    -113.82 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,489.49
    +3.99 (+0.27%)
     
  • Jakarta Composite Index

    6,890.57
    +28.31 (+0.41%)
     
  • PSE Index

    6,986.19
    -49.57 (-0.70%)
     

Vertex to Participate in Upcoming Investor Conferences

BOSTON, November 09, 2022--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences:

  • Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 9:10 a.m. GMT (4:10 a.m. EST)

  • 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022, at 9:15 a.m. EST

A live webcast of management’s remarks will be available through Vertex’s website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcasts will be archived on the company’s website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune’s Best Workplaces in Biotechnology and Pharmaceuticals and Best Workplaces for Women. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005068/en/

Contacts

Vertex Pharmaceuticals Incorporated Investor Relations:
Susie Lisa, 617-341-6108
Manisha Pai, 617-961-1899
Miroslava Minkova, 617-341-6135